There are currently 32 active clinical trials seeking participants for Pulmonary Hypertension research studies. The states with the highest number of trials for Pulmonary Hypertension participants are California, Florida, New York and Ohio.
Development of an Algorithm to Detect Pulmonary Hypertension Using an Electronic Stethoscope
NCT05873387
Recruiting
The major goal of the study is to determine whether phonocardiography (using the Eko DUO stethoscope which can capture a three lead ECG reading) can present features that relate to the presence of PH diagnosed by echocardiography or right heart catheterization (RHC), and therefore have a potential to assist the provider to suspect PH.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/15/2025
Locations: Rhode Island Hospital, Providence, Rhode Island +2 locations
Conditions: Pulmonary Hypertension
Register for Updates
LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF
NCT05983250
Recruiting
This study will evaluate the efficacy of TNX-103 (oral levosimendan) compared with placebo in subjects with PH-HFpEF as measured by the change in 6-Minute Walk Distance (6 MWD; Day 1 to Week 12).
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
08/15/2025
Locations: Tenax Investigational Site, Birmingham, Alabama +53 locations
Conditions: Pulmonary Hypertension
Register for Updates
Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure
NCT06526195
Recruiting
The purpose of TEAM-HF IDE clinical trial is to evaluate safety and effectiveness of the HeartMate 3 LVAS compared to guideline directed medical therapy (GDMT) in a population of ambulatory advanced heart failure patients who are not dependent on intravenous inotrope.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/08/2025
Locations: Banner-University Medical Center Phoenix, Phoenix, Arizona +42 locations
Conditions: Heart Failure, Heart Diseases, Cardiovascular Diseases, Pulmonary Hypertension
Register for Updates
Natural History Study of Biomarkers in Pulmonary Arterial Hypertension
NCT01730092
Recruiting
Background: - High blood pressure in the lungs, known as pulmonary arterial hypertension (PAH), is a rare disorder. Some people have disease-associated PAH and some have PAH from an unknown cause. Researchers want to follow the natural history of all PAH patients to understand how PAH progresses in order to discover targets for future research into new treatments. To further identify treatment targets, they will compare healthy volunteers to patients with PAH. Objectives: - To study the natur... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
08/07/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Pulmonary Disease, Pulmonary Hypertension
Register for Updates
Pulmonary Hypertension Biorepository and Registry
NCT04808596
Recruiting
Establish a pulmonary hypertension registry and biorepository to lead towards a further understanding of the disease.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/29/2025
Locations: University of Kansas Medical Center, Kansas City, Kansas
Conditions: Pulmonary Hypertension, Pulmonary Arterial Hypertension, Pulmonary Hypertension Due to Left Heart Disease, Pulmonary Hypertension, Primary, Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Pulmonary Hypertension, Primary, 4, Pulmonary Hypertension, Primary, 2, Pulmonary Hypertension, Primary, 3, Chronic Thromboembolic Pulmonary Hypertension
Register for Updates
Pulmonary Hypertension Association Registry
NCT04071327
Recruiting
The PHA Registry (PHAR) is a national study about people who have pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). PHAR collects information from people with PAH and CTEPH who are cared for in participating PHA-accredited Pulmonary Hypertension Care Centers throughout the U.S. PHAR will determine how people with PAH and CTEPH are evaluated, tested, and treated, and will observe how well these participants do. The goal is to see if people with PH a... Read More
Gender:
ALL
Ages:
0 years and above
Trial Updated:
07/28/2025
Locations: Arizona Pulmonary Specialists, Ltd., Phoenix, Arizona +51 locations
Conditions: Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension, Pulmonary Hypertension
Register for Updates
Frespaciguat (MK-5475) INSIGNIA-PH-COPD: A Study of the Efficacy and Safety of Frespaciguat (an Inhaled sGC Stimulator) in Adults With PH-COPD
NCT05612035
Recruiting
Researchers are looking for ways to treat pulmonary hypertension (PH) caused by chronic obstructive pulmonary disease (COPD). The goal of the study is to learn if people who take frespaciguat can walk farther in 6 minutes at Week 24 compared to people who take placebo.
Gender:
ALL
Ages:
Between 40 years and 85 years
Trial Updated:
07/24/2025
Locations: UCSF Helen Diller Medical Center at Parnassus Heights ( Site 0110), San Francisco, California +83 locations
Conditions: Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
Register for Updates
Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension
NCT06911632
Recruiting
MOMENTOUS is a multi-center, randomized study to prospectively evaluate the performance of an ECG-based AI device to predict whether participants with interstitial lung disease (ILD) are at high risk of undiagnosed pulmonary hypertension.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/23/2025
Locations: Dignity Health - St. Joseph's Hospital and Medical Center-Norton Thoracic Institute, Phoenix, Arizona +4 locations
Conditions: Pulmonary Hypertension, Interstitial Lung Disease (ILD)
Register for Updates
Xenon MRI Pulm Hypertension
NCT04991454
Recruiting
The overall objective outlined in this study is to determine how pulmonary vascular remodeling in PAH at a cellular and pathological level is associated with changes in gas exchange physiology and hemodynamics (monitored with 129Xe MRI/MRS) and how these signals change with disease progression or treatment.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/21/2025
Locations: Duke University Medical Center, Durham, North Carolina
Conditions: Pulmonary Hypertension, Pulmonary Arterial Hypertension
Register for Updates
DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
NCT06388421
Recruiting
This is a prospective, non-interventional, multicenter, registry of patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/08/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +21 locations
Conditions: Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Pulmonary Hypertension, Interstitial Lung Disease
Register for Updates
Bioenergetic Effect of Pioglitazone in CLD-PH
NCT06336798
Recruiting
The goal of this clinical trial is to learn about the safety and efficacy of Pioglitazone in people with Pulmonary Hypertension (PH) due to Chronic Lung Disease (CLD). The main question it aims to answer is: • Whether pioglitazone affects mitochondrial oxygen utilization in patients with PH due to CLD. Participants will be asked to take pioglitazone or placebo once daily for 28 days followed by a washout period of 2 weeks followed by 28 days of the other study drug (participants randomized to... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/02/2025
Locations: Emory Healthcare System, Atlanta, Georgia
Conditions: Pulmonary Hypertension, Pulmonary Hypertension Due to Lung Diseases
Register for Updates
Pulmonary Hypertension Screening in Patients With Interstitial Lung Disease for Earlier Detection
NCT05776225
Recruiting
Study GMS-PH-001 is a multicenter, open-label, non-randomized study to prospectively evaluate screening strategies of pulmonary hypertension (PH) in patients with interstitial lung disease (ILD).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/27/2025
Locations: Pulmonary Associates, Phoenix, Arizona +41 locations
Conditions: Interstitial Lung Disease, Pulmonary Hypertension
Register for Updates